FOLH1 and neoplasm: Compared with [177Lu]Lu-PSMA I&T, [177Lu]Lu-rhPSMA-7.3 exhibited a 2.8- and 4.7-fold higher tumor uptake at 1 and 168 h after injection, respectively, resulting in a significantly higher dose at the tumor and a superior treatment response (13).